A new therapeutic drug that suppresses the action of the new coronavirus by administering antibodies is expected to be approved on the night of the 27th.
This is the second drug that can be used for mildly ill patients, following antibody cocktail therapy.
Sotrovimab, which is expected to be approved by the British pharmaceutical giant GlaxoSmithKline, has applied for approval from the Ministry of Health, Labor and Welfare.
The target patients are mild or moderately ill patients who are at high risk of aggravation and do not need oxygen administration, and "neutralizing antibody" that suppresses the action of the new coronavirus is administered by intravenous drip.
In clinical trials conducted overseas, the effect of reducing the risk of hospitalization and death by 79% was confirmed, and in May this year, emergency use permission was issued in the United States.
On the 27th, the expert committee of the Ministry of Health, Labor and Welfare examined the approval or disapproval, and the approval in Japan was approved as the effectiveness and safety were recognized.
In response to this, the Ministry of Health, Labor and Welfare is expected to officially approve it on the night of the 27th.
This is the second drug that can be used for mildly ill patients, following antibody cocktail therapy, and is expected to help prevent the aggravation of more patients.